Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 17/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050240 | 0.93 | SCD (0.58) | SCDCHRM4 | |
| SCHEMBL3042773 | 0.93 | SCD (0.65) | SCD | |
| SCHEMBL3043662 | 0.93 | SCD (0.66) | SCD | |
| SCHEMBL3052612 | 0.87 | SCD (0.62) | SCD | |
| SCHEMBL3047518 | 0.87 | SCD (0.65) | SCD | |
| SCHEMBL3056280 | 0.86 | SCD (0.58) | SCD | |
| SCHEMBL3050244 | 0.86 | SCD (0.61) | SCD | |
| SCHEMBL3037174 | 0.84 | SCD (0.70) | SCD | |
| SCHEMBL3050225 | 0.84 | SCD (0.57) | SCDCHRM4 | |
| SCHEMBL3047339 | 0.84 | SCD (0.59) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | claimed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | claimed |
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | disclosed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | disclosed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | disclosed |
| WO-2008036715-A1 | HETEROCYCLIC ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029718-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885CHRM4 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.